Newsfeeds - Spark Newswire

3 minute read

PacBio Announces Onso, The Highly Accurate Short-Read Sequencing Platform

Today, 7:29 PM

The Onso Sequencing System is Designed to Deliver Industry-Leading Sensitivity and Specificity for Novel Insights in Oncology and Disease Research MENLO PARK, Calif., Oct. 25, 2022 /PRNewswire/

PACB

3 minute read

PacBio Announces Revio, A Revolutionary New Long Read Sequencing System Designed To Provide 15 Times More HiFi Data And Human Genomes At Scale For Under $1,000

By Benzinga Newsdesk

Today, 7:29 PM

Significant Advances in SMRT Cell Design, Compute, and a New System Architecture Will Enable Revio to Dramatically Increase Throughput and Lower Cost While Leveraging the Power of HiFi for Exceptional Accuracy and Direct Methylation Detection

PACB

5 minute read

Why Huntington Bancshares Shares Surged Around 10%; Here Are 72 Biggest Movers From Friday

By Lisa Levin

Today, 7:29 PM

Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) jumped 89.3% to close at $58.92 on Friday.

ALF

2 minute read

Moderna, Amazon, Tesla, And Other Big Gainers From Friday

By Lisa Levin

Today, 7:29 PM

U.S. stocks closed higher on Friday, with the Dow Jones gaining around 750 points. Here is the list of some big stocks recording gains in the previous session.

AMZN

5 minute read

Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday

By Lisa Levin

Today, 7:29 PM

Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial met its primary endpoint.

ABOS

4 minute read

Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

Today, 7:29 PM

Gainers

ABOS

6 minute read

Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday

By Lisa Levin

Today, 7:29 PM

Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX dose groups.

AAPL